Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to be Presented from ARISE Examining Change in Patient-Reported Respiratory Symptoms—...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news